Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) in combined treatment of ovarian cancer: time for the beginning of personalized therapy?

Data publikacji: 28 wrz 2019

Zakres stron: 154 - 159

Otrzymano: 08 sty 2019

Przyjęty: 27 mar 2019

DOI: https://doi.org/10.2478/cipms-2019-0028

Słowa kluczowe

ovarian cancer, peritoneal carcinomatosis, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, p53, BRCA 1

© 2019 Roman Yarema et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.